Environmental and Social Data Sheet

Overview

<table>
<thead>
<tr>
<th>Project Name:</th>
<th>EXEVIR (COVID-19) (IDFF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Number:</td>
<td>20210619</td>
</tr>
<tr>
<td>Country:</td>
<td>Belgium</td>
</tr>
<tr>
<td>Project Description:</td>
<td>The Promoter is a Belgium-based clinical stage company that develops single-domain antibody-based therapies (VHH or nanobodies). The Project supports the development of the Company’s lead product, XVR012 in COVID-19, including inter alia clinical and regulatory approvals in the EU and the US, scale-up of manufacturing operations and the R&amp;D activities for a sub-cutaneous formulation.</td>
</tr>
</tbody>
</table>

EIA required: no

Project included in Carbon Footprint Exercise*: no

Environmental and Social Assessment

Environmental Assessment

The project concerns investments in research and development activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The project does not fall under the scope of the EIA Directive 2014/52/EU amending Directive 2011/92/EU.

The Promoter maintains adequate internal procedures and management practices that are in line with best industry standards (e.g. GMP) and are subjected to audits. The project will be carried out according to state-of-the-art technology and will take into consideration environmentally friendly, low energy-and-resource consuming technologies.

Other Environmental and Social Aspects

If successful, the project is expected to lead to important social benefits, considering the targeted indications and the level of unmet medical need.

The project supports research into the virus SARS-CoV-2 that causes COVID 19 and it therefore contributes to the EU coordinated response to the COVID 19 crisis. Successful

* Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO2e/year absolute (gross) or 20,000 tonnes CO2e/year relative (net) – both increases and savings.
therapeutics to combat the disease and curb the pandemic will reinforce public health sectors and mitigate the socio-economic impact of the disease globally.

Through the R&D activities and investments, the Promoter is also expected to create skilled employment opportunities, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

## Conclusions and Recommendations

The project concerns investments in research and development activities, carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The project does not fall under the scope of the EIA Directive 2014/52/EU amending Directive 2011/92/EU.

The project will not result in any significant additional negative environmental and social impacts.

Considering the above, the project is considered acceptable for the Bank financing in environmental and social terms.